These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 21599797

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
    Hocquet D, Nordmann P, El Garch F, Cabanne L, Plésiat P.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
    [Abstract] [Full Text] [Related]

  • 6. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.
    Islam S, Jalal S, Wretlind B.
    Clin Microbiol Infect; 2004 Oct; 10(10):877-83. PubMed ID: 15373880
    [Abstract] [Full Text] [Related]

  • 7. Mutational analyses of regulatory genes, mexR, nalC, nalD and mexZ of mexAB-oprM and mexXY operons, in efflux pump hyperexpressing multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Suresh M, Nithya N, Jayasree PR, Vimal KP, Manish Kumar PR.
    World J Microbiol Biotechnol; 2018 May 30; 34(6):83. PubMed ID: 29846800
    [Abstract] [Full Text] [Related]

  • 8. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI).
    Antimicrob Agents Chemother; 2011 May 30; 55(5):1906-11. PubMed ID: 21357294
    [Abstract] [Full Text] [Related]

  • 9. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B.
    APMIS; 2005 Mar 30; 113(3):187-96. PubMed ID: 15799762
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM, Choi JY, Lee JY, Kang CI, Chung DR, Peck KR, Song JH, Ko KS.
    Antimicrob Agents Chemother; 2017 Jun 30; 61(6):. PubMed ID: 28373200
    [Abstract] [Full Text] [Related]

  • 11. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F.
    Int J Antimicrob Agents; 2018 Nov 30; 52(5):697-701. PubMed ID: 30081137
    [Abstract] [Full Text] [Related]

  • 12. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa.
    Kiser TH, Obritsch MD, Jung R, MacLaren R, Fish DN.
    Pharmacotherapy; 2010 Jul 30; 30(7):632-8. PubMed ID: 20575627
    [Abstract] [Full Text] [Related]

  • 13. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.
    Peña C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MA, Oliver A, Pujol M, Ariza J.
    J Clin Microbiol; 2009 Aug 30; 47(8):2381-7. PubMed ID: 19494059
    [Abstract] [Full Text] [Related]

  • 14. Meropenem susceptibility breakpoint for Pseudomonas aeruginosa strains hyperproducing mexB mRNA.
    Giske CG, Borén C, Wretlind B, Kronvall G.
    Clin Microbiol Infect; 2005 Aug 30; 11(8):662-9. PubMed ID: 16008620
    [Abstract] [Full Text] [Related]

  • 15. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M, Fàbrega A, Cobos-Trigueros N, Zamorano L, Ferrer-Navarro M, Ballesté-Delpierre C, Reustle A, Castro P, Nicolás JM, Oliver A, Martínez JA, Vila J.
    J Antimicrob Chemother; 2015 Nov 30; 70(11):3004-13. PubMed ID: 26260130
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital.
    Hammami S, Ghozzi R, Burghoffer B, Arlet G, Redjeb S.
    Pathol Biol (Paris); 2009 Nov 30; 57(7-8):530-5. PubMed ID: 18977099
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.
    Pan YP, Xu YH, Wang ZX, Fang YP, Shen JL.
    Arch Microbiol; 2016 Aug 30; 198(6):565-71. PubMed ID: 27060003
    [Abstract] [Full Text] [Related]

  • 18. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.
    J Antimicrob Chemother; 2011 Sep 30; 66(9):2022-7. PubMed ID: 21653605
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Feb 30; 57(2):153-61. PubMed ID: 16930925
    [Abstract] [Full Text] [Related]

  • 20. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
    Yi MY, Wang PY, Huang HJ, Liu YC.
    Zhonghua Yi Xue Za Zhi; 2006 Feb 21; 86(7):457-62. PubMed ID: 16677571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.